nodes	percent_of_prediction	percent_of_DWPC	metapath
Trisalicylate-choline—PTGS1—esophageal cancer	0.539	0.636	CbGaD
Trisalicylate-choline—PTGS2—esophageal cancer	0.308	0.364	CbGaD
Trisalicylate-choline—PTGS2—Cisplatin—esophageal cancer	0.0848	1	CbGbCtD
Trisalicylate-choline—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—ALOX15—esophageal cancer	0.00341	0.0724	CbGpPWpGaD
Trisalicylate-choline—Magnesium salicylate—PTGS1—esophageal cancer	0.00164	0.344	CrCbGaD
Trisalicylate-choline—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—esophageal cancer	0.00153	0.0324	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Eicosanoid Synthesis—ALOX15—esophageal cancer	0.00142	0.0301	CbGpPWpGaD
Trisalicylate-choline—Salsalate—PTGS1—esophageal cancer	0.00139	0.292	CrCbGaD
Trisalicylate-choline—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—esophageal cancer	0.00132	0.0281	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Calcium signaling in the CD4+ TCR pathway—FKBP1A—esophageal cancer	0.00125	0.0264	CbGpPWpGaD
Trisalicylate-choline—Localized exfoliation—Capecitabine—esophageal cancer	0.00124	0.0739	CcSEcCtD
Trisalicylate-choline—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS1—esophageal cancer	0.0012	0.0255	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—CYP2A6—esophageal cancer	0.00114	0.0241	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Eicosanoid Synthesis—ALOX15—esophageal cancer	0.00113	0.0239	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Overview of nanoparticle effects—PTGS1—esophageal cancer	0.00094	0.0199	CbGpPWpGaD
Trisalicylate-choline—Magnesium salicylate—PTGS2—esophageal cancer	0.000937	0.197	CrCbGaD
Trisalicylate-choline—PTGS1—Overview of nanoparticle effects—HMOX1—esophageal cancer	0.000864	0.0183	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Prostaglandin Synthesis and Regulation—ANXA1—esophageal cancer	0.000806	0.0171	CbGpPWpGaD
Trisalicylate-choline—Salsalate—PTGS2—esophageal cancer	0.000797	0.167	CrCbGaD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000788	0.0167	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Overview of nanoparticle effects—BAX—esophageal cancer	0.000784	0.0166	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Eicosanoid Synthesis—PTGS1—esophageal cancer	0.00078	0.0165	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.000742	0.0157	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.000742	0.0157	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC52A3—esophageal cancer	0.000699	0.0148	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000695	0.0147	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Overview of nanoparticle effects—HMOX1—esophageal cancer	0.000686	0.0146	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Prostaglandin Synthesis and Regulation—PTGS1—esophageal cancer	0.000652	0.0138	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Prostaglandin Synthesis and Regulation—ANXA1—esophageal cancer	0.00064	0.0136	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000625	0.0133	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Overview of nanoparticle effects—BAX—esophageal cancer	0.000623	0.0132	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CA1—esophageal cancer	0.000611	0.013	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000609	0.0129	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.000589	0.0125	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.000589	0.0125	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—esophageal cancer	0.000579	0.0123	CbGpPWpGaD
Trisalicylate-choline—Gastric ulcer—Capecitabine—esophageal cancer	0.000573	0.0342	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.000568	0.0121	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000566	0.012	CbGpPWpGaD
Trisalicylate-choline—PTGS2—S1P1 pathway—KDR—esophageal cancer	0.000515	0.0109	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Overview of nanoparticle effects—BCL2—esophageal cancer	0.000478	0.0101	CbGpPWpGaD
Trisalicylate-choline—Hearing impaired—Cisplatin—esophageal cancer	0.000475	0.0284	CcSEcCtD
Trisalicylate-choline—Pain—Carboplatin—esophageal cancer	0.00047	0.0281	CcSEcCtD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000464	0.00985	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Overview of nanoparticle effects—PTGS2—esophageal cancer	0.000454	0.00963	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000433	0.0092	CbGpPWpGaD
Trisalicylate-choline—Skin exfoliation—Cisplatin—esophageal cancer	0.000431	0.0258	CcSEcCtD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000429	0.00911	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—FKBP1A—esophageal cancer	0.000405	0.0086	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000404	0.00856	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.000394	0.00836	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO1—esophageal cancer	0.000383	0.00813	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Overview of nanoparticle effects—BCL2—esophageal cancer	0.000379	0.00805	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Eicosanoid Synthesis—PTGS2—esophageal cancer	0.000376	0.00799	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Biological oxidations—ADH7—esophageal cancer	0.000369	0.00783	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000369	0.00782	CbGpPWpGaD
Trisalicylate-choline—Deafness—Cisplatin—esophageal cancer	0.000367	0.0219	CcSEcCtD
Trisalicylate-choline—Hypocalcaemia—Capecitabine—esophageal cancer	0.000364	0.0217	CcSEcCtD
Trisalicylate-choline—Burning sensation—Methotrexate—esophageal cancer	0.000357	0.0213	CcSEcCtD
Trisalicylate-choline—Hearing impaired—Capecitabine—esophageal cancer	0.00035	0.0209	CcSEcCtD
Trisalicylate-choline—Stupor—Methotrexate—esophageal cancer	0.000332	0.0198	CcSEcCtD
Trisalicylate-choline—Injection site reaction—Capecitabine—esophageal cancer	0.000331	0.0198	CcSEcCtD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000325	0.0069	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Biological oxidations—ADH1B—esophageal cancer	0.000324	0.00687	CbGpPWpGaD
Trisalicylate-choline—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000322	0.0192	CcSEcCtD
Trisalicylate-choline—Skin exfoliation—Capecitabine—esophageal cancer	0.000318	0.019	CcSEcCtD
Trisalicylate-choline—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—esophageal cancer	0.000315	0.00668	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000306	0.00649	CbGpPWpGaD
Trisalicylate-choline—Oesophagitis—Capecitabine—esophageal cancer	0.000304	0.0182	CcSEcCtD
Trisalicylate-choline—Ecchymosis—Capecitabine—esophageal cancer	0.000301	0.018	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—CYP26A1—esophageal cancer	0.000301	0.00638	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—esophageal cancer	0.000301	0.00638	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Biological oxidations—GSTO1—esophageal cancer	0.00028	0.00594	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—PTGS1—esophageal cancer	0.000276	0.00585	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000276	0.00585	CbGpPWpGaD
Trisalicylate-choline—Abdominal discomfort—Cisplatin—esophageal cancer	0.000272	0.0162	CcSEcCtD
Trisalicylate-choline—Deafness—Capecitabine—esophageal cancer	0.00027	0.0162	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—LGALS3—esophageal cancer	0.000265	0.00563	CbGpPWpGaD
Trisalicylate-choline—Lethargy—Capecitabine—esophageal cancer	0.000247	0.0147	CcSEcCtD
Trisalicylate-choline—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000239	0.0143	CcSEcCtD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000237	0.00503	CbGpPWpGaD
Trisalicylate-choline—Skin exfoliation—Methotrexate—esophageal cancer	0.000237	0.0141	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—CXCL2—esophageal cancer	0.00023	0.00488	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Biological oxidations—ALDH2—esophageal cancer	0.000228	0.00484	CbGpPWpGaD
Trisalicylate-choline—Ecchymosis—Methotrexate—esophageal cancer	0.000224	0.0134	CcSEcCtD
Trisalicylate-choline—Abdominal pain upper—Capecitabine—esophageal cancer	0.000221	0.0132	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—GSTT1—esophageal cancer	0.000217	0.0046	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000216	0.00458	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Biological oxidations—CYP2A6—esophageal cancer	0.000214	0.00455	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000214	0.00454	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—ANXA1—esophageal cancer	0.000214	0.00454	CbGpPWpGaD
Trisalicylate-choline—Tinnitus—Cisplatin—esophageal cancer	0.000212	0.0126	CcSEcCtD
Trisalicylate-choline—Flushing—Cisplatin—esophageal cancer	0.000211	0.0126	CcSEcCtD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000209	0.00444	CbGpPWpGaD
Trisalicylate-choline—Asthma—Capecitabine—esophageal cancer	0.000209	0.0125	CcSEcCtD
Trisalicylate-choline—Abdominal discomfort—Capecitabine—esophageal cancer	0.0002	0.012	CcSEcCtD
Trisalicylate-choline—Erythema—Cisplatin—esophageal cancer	0.000198	0.0118	CcSEcCtD
Trisalicylate-choline—Weight increased—Capecitabine—esophageal cancer	0.00019	0.0114	CcSEcCtD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000188	0.00399	CbGpPWpGaD
Trisalicylate-choline—Lethargy—Methotrexate—esophageal cancer	0.000184	0.011	CcSEcCtD
Trisalicylate-choline—Epistaxis—Capecitabine—esophageal cancer	0.000176	0.0105	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—CYP1B1—esophageal cancer	0.000173	0.00367	CbGpPWpGaD
Trisalicylate-choline—Hepatitis—Capecitabine—esophageal cancer	0.000167	0.01	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000167	0.00354	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Biological oxidations—CYP19A1—esophageal cancer	0.000162	0.00345	CbGpPWpGaD
Trisalicylate-choline—Oedema—Cisplatin—esophageal cancer	0.000161	0.00963	CcSEcCtD
Trisalicylate-choline—Erythema multiforme—Capecitabine—esophageal cancer	0.000158	0.00945	CcSEcCtD
Trisalicylate-choline—Tinnitus—Capecitabine—esophageal cancer	0.000156	0.00932	CcSEcCtD
Trisalicylate-choline—Hyperhidrosis—Cisplatin—esophageal cancer	0.000156	0.00931	CcSEcCtD
Trisalicylate-choline—Asthma—Methotrexate—esophageal cancer	0.000156	0.0093	CcSEcCtD
Trisalicylate-choline—Flushing—Capecitabine—esophageal cancer	0.000155	0.00928	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000155	0.00329	CbGpPWpGaD
Trisalicylate-choline—Anorexia—Cisplatin—esophageal cancer	0.000154	0.00918	CcSEcCtD
Trisalicylate-choline—Hypotension—Cisplatin—esophageal cancer	0.000151	0.009	CcSEcCtD
Trisalicylate-choline—Abdominal discomfort—Methotrexate—esophageal cancer	0.000149	0.00891	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000148	0.00313	CbGpPWpGaD
Trisalicylate-choline—Erythema—Capecitabine—esophageal cancer	0.000146	0.0087	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000145	0.00309	CbGpPWpGaD
Trisalicylate-choline—Dysgeusia—Capecitabine—esophageal cancer	0.000143	0.00852	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Cisplatin—esophageal cancer	0.00014	0.00837	CcSEcCtD
Trisalicylate-choline—Drowsiness—Methotrexate—esophageal cancer	0.000139	0.00829	CcSEcCtD
Trisalicylate-choline—Pain—Cisplatin—esophageal cancer	0.000138	0.00824	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000134	0.00284	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—PTGS2—esophageal cancer	0.000133	0.00282	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000133	0.00282	CbGpPWpGaD
Trisalicylate-choline—Sweating—Methotrexate—esophageal cancer	0.000133	0.00795	CcSEcCtD
Trisalicylate-choline—Feeling abnormal—Cisplatin—esophageal cancer	0.000133	0.00794	CcSEcCtD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000132	0.00281	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.000132	0.00279	CbGpPWpGaD
Trisalicylate-choline—Epistaxis—Methotrexate—esophageal cancer	0.000131	0.00782	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000129	0.00273	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000127	0.00269	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000126	0.00267	CbGpPWpGaD
Trisalicylate-choline—Hepatitis—Methotrexate—esophageal cancer	0.000125	0.00744	CcSEcCtD
Trisalicylate-choline—Confusional state—Capecitabine—esophageal cancer	0.00012	0.00716	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—TLR4—esophageal cancer	0.000119	0.00254	CbGpPWpGaD
Trisalicylate-choline—Oedema—Capecitabine—esophageal cancer	0.000119	0.0071	CcSEcCtD
Trisalicylate-choline—Erythema multiforme—Methotrexate—esophageal cancer	0.000118	0.00704	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.000117	0.00249	CbGpPWpGaD
Trisalicylate-choline—Shock—Capecitabine—esophageal cancer	0.000117	0.00699	CcSEcCtD
Trisalicylate-choline—Tinnitus—Methotrexate—esophageal cancer	0.000116	0.00694	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—BCL2—esophageal cancer	0.000115	0.00245	CbGpPWpGaD
Trisalicylate-choline—Hyperhidrosis—Capecitabine—esophageal cancer	0.000115	0.00687	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—NOS2—esophageal cancer	0.000114	0.00241	CbGpPWpGaD
Trisalicylate-choline—Anorexia—Capecitabine—esophageal cancer	0.000113	0.00677	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000113	0.00239	CbGpPWpGaD
Trisalicylate-choline—Hypotension—Capecitabine—esophageal cancer	0.000111	0.00664	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Cisplatin—esophageal cancer	0.00011	0.00659	CcSEcCtD
Trisalicylate-choline—Erythema—Methotrexate—esophageal cancer	0.000108	0.00648	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000107	0.00228	CbGpPWpGaD
Trisalicylate-choline—Dysgeusia—Methotrexate—esophageal cancer	0.000106	0.00634	CcSEcCtD
Trisalicylate-choline—Dyspepsia—Capecitabine—esophageal cancer	0.000105	0.00625	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000104	0.0022	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000104	0.0022	CbGpPWpGaD
Trisalicylate-choline—Decreased appetite—Capecitabine—esophageal cancer	0.000103	0.00617	CcSEcCtD
Trisalicylate-choline—Vomiting—Cisplatin—esophageal cancer	0.000103	0.00613	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—RB1—esophageal cancer	0.000102	0.00216	CbGpPWpGaD
Trisalicylate-choline—Rash—Cisplatin—esophageal cancer	0.000102	0.00607	CcSEcCtD
Trisalicylate-choline—Pain—Capecitabine—esophageal cancer	0.000102	0.00607	CcSEcCtD
Trisalicylate-choline—Constipation—Capecitabine—esophageal cancer	0.000102	0.00607	CcSEcCtD
Trisalicylate-choline—Dermatitis—Cisplatin—esophageal cancer	0.000102	0.00607	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CCND1—esophageal cancer	9.91e-05	0.0021	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	9.83e-05	0.00209	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	9.82e-05	0.00208	CbGpPWpGaD
Trisalicylate-choline—Feeling abnormal—Capecitabine—esophageal cancer	9.79e-05	0.00585	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CDKN1A—esophageal cancer	9.59e-05	0.00203	CbGpPWpGaD
Trisalicylate-choline—Nausea—Cisplatin—esophageal cancer	9.58e-05	0.00572	CcSEcCtD
Trisalicylate-choline—Urticaria—Capecitabine—esophageal cancer	9.44e-05	0.00564	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—EP300—esophageal cancer	9.12e-05	0.00194	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	8.94e-05	0.0019	CbGpPWpGaD
Trisalicylate-choline—Confusional state—Methotrexate—esophageal cancer	8.92e-05	0.00533	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism—BLVRB—esophageal cancer	8.73e-05	0.00185	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—SLC52A3—esophageal cancer	8.73e-05	0.00185	CbGpPWpGaD
Trisalicylate-choline—Hyperhidrosis—Methotrexate—esophageal cancer	8.55e-05	0.00511	CcSEcCtD
Trisalicylate-choline—Anorexia—Methotrexate—esophageal cancer	8.43e-05	0.00504	CcSEcCtD
Trisalicylate-choline—Pruritus—Capecitabine—esophageal cancer	8.41e-05	0.00502	CcSEcCtD
Trisalicylate-choline—PTGS2—Disease—SLC52A3—esophageal cancer	8.28e-05	0.00176	CbGpPWpGaD
Trisalicylate-choline—Hypotension—Methotrexate—esophageal cancer	8.27e-05	0.00494	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Capecitabine—esophageal cancer	8.13e-05	0.00486	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—MYC—esophageal cancer	7.95e-05	0.00169	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—KMT2D—esophageal cancer	7.89e-05	0.00168	CbGpPWpGaD
Trisalicylate-choline—Somnolence—Methotrexate—esophageal cancer	7.87e-05	0.0047	CcSEcCtD
Trisalicylate-choline—Dizziness—Capecitabine—esophageal cancer	7.86e-05	0.0047	CcSEcCtD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	7.8e-05	0.00165	CbGpPWpGaD
Trisalicylate-choline—Dyspepsia—Methotrexate—esophageal cancer	7.79e-05	0.00465	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Methotrexate—esophageal cancer	7.69e-05	0.0046	CcSEcCtD
Trisalicylate-choline—Pain—Methotrexate—esophageal cancer	7.57e-05	0.00452	CcSEcCtD
Trisalicylate-choline—Vomiting—Capecitabine—esophageal cancer	7.56e-05	0.00452	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	7.55e-05	0.0016	CbGpPWpGaD
Trisalicylate-choline—Rash—Capecitabine—esophageal cancer	7.49e-05	0.00448	CcSEcCtD
Trisalicylate-choline—Dermatitis—Capecitabine—esophageal cancer	7.49e-05	0.00447	CcSEcCtD
Trisalicylate-choline—Headache—Capecitabine—esophageal cancer	7.45e-05	0.00445	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism—CA1—esophageal cancer	7.42e-05	0.00158	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—SLC10A2—esophageal cancer	7.42e-05	0.00158	CbGpPWpGaD
Trisalicylate-choline—Feeling abnormal—Methotrexate—esophageal cancer	7.29e-05	0.00436	CcSEcCtD
Trisalicylate-choline—Nausea—Capecitabine—esophageal cancer	7.06e-05	0.00422	CcSEcCtD
Trisalicylate-choline—Urticaria—Methotrexate—esophageal cancer	7.03e-05	0.0042	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	6.97e-05	0.00148	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	6.94e-05	0.00147	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—SLC52A3—esophageal cancer	6.93e-05	0.00147	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—BLVRB—esophageal cancer	6.93e-05	0.00147	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—CA2—esophageal cancer	6.79e-05	0.00144	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	6.64e-05	0.00141	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—ADH7—esophageal cancer	6.31e-05	0.00134	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PLCE1—esophageal cancer	6.31e-05	0.00134	CbGpPWpGaD
Trisalicylate-choline—Pruritus—Methotrexate—esophageal cancer	6.26e-05	0.00374	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	6.24e-05	0.00132	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	6.2e-05	0.00131	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—FKBP1A—esophageal cancer	6.12e-05	0.0013	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	6.06e-05	0.00129	CbGpPWpGaD
Trisalicylate-choline—Diarrhoea—Methotrexate—esophageal cancer	6.05e-05	0.00362	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.98e-05	0.00127	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—WIF1—esophageal cancer	5.98e-05	0.00127	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—DOCK2—esophageal cancer	5.98e-05	0.00127	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	5.92e-05	0.00126	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CA1—esophageal cancer	5.89e-05	0.00125	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—SLC10A2—esophageal cancer	5.89e-05	0.00125	CbGpPWpGaD
Trisalicylate-choline—Dizziness—Methotrexate—esophageal cancer	5.85e-05	0.0035	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	5.81e-05	0.00123	CbGpPWpGaD
Trisalicylate-choline—Vomiting—Methotrexate—esophageal cancer	5.63e-05	0.00336	CcSEcCtD
Trisalicylate-choline—Rash—Methotrexate—esophageal cancer	5.58e-05	0.00333	CcSEcCtD
Trisalicylate-choline—Dermatitis—Methotrexate—esophageal cancer	5.57e-05	0.00333	CcSEcCtD
Trisalicylate-choline—Headache—Methotrexate—esophageal cancer	5.54e-05	0.00331	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism—ADH1B—esophageal cancer	5.53e-05	0.00117	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—CSNK1A1—esophageal cancer	5.52e-05	0.00117	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CA2—esophageal cancer	5.39e-05	0.00114	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—TYMP—esophageal cancer	5.29e-05	0.00112	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.27e-05	0.00112	CbGpPWpGaD
Trisalicylate-choline—Nausea—Methotrexate—esophageal cancer	5.26e-05	0.00314	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism—CYP26A1—esophageal cancer	5.15e-05	0.00109	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	5.14e-05	0.00109	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—ALOX15—esophageal cancer	5.01e-05	0.00106	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ADH7—esophageal cancer	5.01e-05	0.00106	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PLCE1—esophageal cancer	5.01e-05	0.00106	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	4.97e-05	0.00106	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.97e-05	0.00105	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.95e-05	0.00105	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GSTO1—esophageal cancer	4.78e-05	0.00101	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—TPI1—esophageal cancer	4.78e-05	0.00101	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.73e-05	0.001	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—ELMO1—esophageal cancer	4.64e-05	0.000984	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—ALDOB—esophageal cancer	4.59e-05	0.000973	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—TPI1—esophageal cancer	4.53e-05	0.000962	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—GSTO1—esophageal cancer	4.53e-05	0.000962	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GAPDH—esophageal cancer	4.41e-05	0.000937	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ADH1B—esophageal cancer	4.39e-05	0.000932	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—CRABP1—esophageal cancer	4.37e-05	0.000928	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—ALDOB—esophageal cancer	4.35e-05	0.000922	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—TYMP—esophageal cancer	4.2e-05	0.000891	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—HIST1H2BM—esophageal cancer	4.18e-05	0.000888	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—GAPDH—esophageal cancer	4.18e-05	0.000888	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GNG7—esophageal cancer	4.16e-05	0.000883	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	4.12e-05	0.000874	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CYP26A1—esophageal cancer	4.08e-05	0.000867	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	4.03e-05	0.000855	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ALOX15—esophageal cancer	3.98e-05	0.000845	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—ALDH2—esophageal cancer	3.9e-05	0.000827	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—TPI1—esophageal cancer	3.8e-05	0.000806	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GSTO1—esophageal cancer	3.8e-05	0.000806	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GSTT1—esophageal cancer	3.71e-05	0.000787	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—XIAP—esophageal cancer	3.7e-05	0.000784	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—CYP2A6—esophageal cancer	3.67e-05	0.000778	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.65e-05	0.000775	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ALDOB—esophageal cancer	3.64e-05	0.000772	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GAPDH—esophageal cancer	3.5e-05	0.000744	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.5e-05	0.000742	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—ENO1—esophageal cancer	3.48e-05	0.000737	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CRABP1—esophageal cancer	3.47e-05	0.000737	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—B2M—esophageal cancer	3.44e-05	0.000729	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PSME2—esophageal cancer	3.42e-05	0.000727	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PSME1—esophageal cancer	3.42e-05	0.000727	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.38e-05	0.000718	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GNG7—esophageal cancer	3.3e-05	0.000701	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—ENO1—esophageal cancer	3.29e-05	0.000699	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—PSME2—esophageal cancer	3.25e-05	0.000689	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—PSME1—esophageal cancer	3.25e-05	0.000689	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—CALR—esophageal cancer	3.12e-05	0.000661	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ALDH2—esophageal cancer	3.1e-05	0.000657	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—FBXW7—esophageal cancer	3.01e-05	0.000639	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.99e-05	0.000635	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—CYP1B1—esophageal cancer	2.96e-05	0.000627	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GSTT1—esophageal cancer	2.94e-05	0.000625	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CYP2A6—esophageal cancer	2.91e-05	0.000618	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.9e-05	0.000615	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—CYP19A1—esophageal cancer	2.78e-05	0.00059	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ENO1—esophageal cancer	2.76e-05	0.000585	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PTGS1—esophageal cancer	2.76e-05	0.000585	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PSME1—esophageal cancer	2.72e-05	0.000577	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PSME2—esophageal cancer	2.72e-05	0.000577	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—HMOX1—esophageal cancer	2.54e-05	0.000538	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.49e-05	0.000528	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—TGFBR2—esophageal cancer	2.44e-05	0.000517	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—ABCB1—esophageal cancer	2.43e-05	0.000516	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CYP1B1—esophageal cancer	2.35e-05	0.000498	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—SMAD4—esophageal cancer	2.31e-05	0.000489	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CYP19A1—esophageal cancer	2.21e-05	0.000468	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—HMOX1—esophageal cancer	2.01e-05	0.000427	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.97e-05	0.000419	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ABCB1—esophageal cancer	1.93e-05	0.00041	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—HIF1A—esophageal cancer	1.89e-05	0.000401	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.84e-05	0.00039	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—NOS2—esophageal cancer	1.72e-05	0.000364	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—NOTCH1—esophageal cancer	1.7e-05	0.000361	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—CREBBP—esophageal cancer	1.63e-05	0.000345	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—CREBBP—esophageal cancer	1.54e-05	0.000327	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.46e-05	0.00031	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—NOS3—esophageal cancer	1.46e-05	0.000309	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—NOS3—esophageal cancer	1.38e-05	0.000293	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PTGS2—esophageal cancer	1.33e-05	0.000283	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CREBBP—esophageal cancer	1.29e-05	0.000274	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—ERBB2—esophageal cancer	1.29e-05	0.000274	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—NOS3—esophageal cancer	1.16e-05	0.000245	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—EP300—esophageal cancer	1.11e-05	0.000235	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—CDKN1A—esophageal cancer	1.1e-05	0.000234	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—EP300—esophageal cancer	1.05e-05	0.000223	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—MYC—esophageal cancer	9.15e-06	0.000194	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—EGFR—esophageal cancer	8.95e-06	0.00019	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—EP300—esophageal cancer	8.79e-06	0.000187	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PIK3CA—esophageal cancer	8.19e-06	0.000174	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—PIK3CA—esophageal cancer	7.77e-06	0.000165	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PIK3CA—esophageal cancer	6.5e-06	0.000138	CbGpPWpGaD
